Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F21%3A43920191" target="_blank" >RIV/00216208:11120/21:43920191 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1111/bjd.19262" target="_blank" >https://doi.org/10.1111/bjd.19262</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/bjd.19262" target="_blank" >10.1111/bjd.19262</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study

Popis výsledku v původním jazyce

BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralises interleukin-17A, a cornerstone cytokine in psoriasis, has shown long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations. OBJECTIVE: To report the long-term (2.5-year) efficacy and safety of secukinumab in nail psoriasis. METHODS: TRANSFIGURE, a double-blind, randomised, placebo-controlled, parallel-group, multicentre Phase 3b study in 198 patients, investigated secukinumab 150 and 300 mg in moderate to severe nail psoriasis patients. RESULTS: At Week 16, the primary endpoint NAil Psoriasis Severity Index (NAPSI) was met, demonstrating superiority of secukinumab to placebo. The effect was sustained over 2.5 years with a large benefit on nail clearance with mean NAPSI improvement of -73.3% and -63.6% with secukinumab 300 and 150 mg, respectively. At 2.5 years, secukinumab demonstrated sustained clinically significant reductions in total mean Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) QoL scores by -52.4% and -18.1%, and 70.2% and 70.9% of patients achieved a weighted NAPPA-PBI (Patient Benefit Index) global score of GREATER-THAN OR EQUAL TO2 with secukinumab 300 and 150 mg, respectively. Patients showed considerable improvements in Euro-QoL 5-Dimension Health Status Questionnaire at 2.5 years, reporting decreased pain and discomfort. No new safety findings were observed. CONCLUSIONS: Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2.5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile.

Název v anglickém jazyce

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study

Popis výsledku anglicky

BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralises interleukin-17A, a cornerstone cytokine in psoriasis, has shown long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations. OBJECTIVE: To report the long-term (2.5-year) efficacy and safety of secukinumab in nail psoriasis. METHODS: TRANSFIGURE, a double-blind, randomised, placebo-controlled, parallel-group, multicentre Phase 3b study in 198 patients, investigated secukinumab 150 and 300 mg in moderate to severe nail psoriasis patients. RESULTS: At Week 16, the primary endpoint NAil Psoriasis Severity Index (NAPSI) was met, demonstrating superiority of secukinumab to placebo. The effect was sustained over 2.5 years with a large benefit on nail clearance with mean NAPSI improvement of -73.3% and -63.6% with secukinumab 300 and 150 mg, respectively. At 2.5 years, secukinumab demonstrated sustained clinically significant reductions in total mean Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) QoL scores by -52.4% and -18.1%, and 70.2% and 70.9% of patients achieved a weighted NAPPA-PBI (Patient Benefit Index) global score of GREATER-THAN OR EQUAL TO2 with secukinumab 300 and 150 mg, respectively. Patients showed considerable improvements in Euro-QoL 5-Dimension Health Status Questionnaire at 2.5 years, reporting decreased pain and discomfort. No new safety findings were observed. CONCLUSIONS: Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2.5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

British Journal of Dermatology

ISSN

0007-0963

e-ISSN

—

Svazek periodika

184

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

425-436

Kód UT WoS článku

000599066000001

EID výsledku v databázi Scopus

2-s2.0-85097133895